Breast Cancer News and Research

Latest Breast Cancer News and Research

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Those cups of coffee that you drink every day to keep alert appear to have an extra perk - especially if you're an older adult. A recent study monitoring the memory and thinking processes of people older than 65 found that all those with higher blood caffeine levels avoided the onset of Alzheimer's disease in the two-to-four years of study follow-up. Moreover, coffee appeared to be the major or only source of caffeine for these individuals.

5 Jun 2012

Androgen receptor an additional hormonal target in many breast cancers

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.

5 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Variation in microRNAs may explain survival differences in breast cancer

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2012

UH CNRCS students achieve significant milestones in cancer therapy research

Four University of Houston (UH) students are well on their way to emerging cancer research careers upon achieving significant milestones this spring in their work toward new therapies for prostate and breast cancer.

2 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

75% increase in cancer incidence predicted by 2030

The global cancer burden is set to surge more than 75% by 2030, according to new research published Online First in the Lancet Oncology. The rise is predicted to be even larger in the developing world, with the poorest countries experiencing a projected increase of more than 90%.

1 Jun 2012

Breast Cancer News and Research

Latest Breast Cancer News and Research

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Androgen receptor an additional hormonal target in many breast cancers

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Variation in microRNAs may explain survival differences in breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

Study reveals why GBM is highly resistant to current chemotherapies

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

UH CNRCS students achieve significant milestones in cancer therapy research

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

America's biopharmaceutical researchers work on many new approaches to fight cancer

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

75% increase in cancer incidence predicted by 2030

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Breast Cancer News and Research

Latest Breast Cancer News and Research

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in